Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @MaisaCorp
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MaisaCorp
-
Prikvačeni tweet
“I’m not greedy. I just want my 1% of
#WallStreet's money." by#MAISAHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
$MBRX intends to discuss a plan with the US and European regulators to conduct a trial that would serve as the basis for accelerated approval of its treatment for relapsed or refractory acute myeloid leukemiaHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$GILD the US patent office Wednesday said it's unlikely the company will win cases challenging the government ownership of the patents underlying HIV drugs.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AIMT Nestle Health Science was making an additional $200 million equity investment in the biopharmaceuticals company, boosting its total investment to $473 million.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$VVUS FDA approved the company's supplemental new drug application for a delayed-release formulation of its pancreaze prescription medicine used to treat people who cannot digest food normally due to pancreas disordersHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$BVXV Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$BLCM R/S 1:10Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AGTC Files For Offering Of 6 Million Shares Of Common StockHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
$CTXR Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial The next major milestone in the Mino-Lok trial, expected to be achieved in the first half of 2020, will be the 75% interim analysis for superior efficacy.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
$GILD Gilead Sciences Sets Quarterly Dividend Of $0.68 Per ShareHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$EYPT has signed an exclusive license agreement with Equinox Science LLC to develop vorolanib, a tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CRMD has been approved by the New Jersey Economic Development Authority to transfer approximately $5.5 million of the total $6.0 million of its available tax benefitsHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CPRX Appoints David Ailinger as Vice President, Business DevelopmentHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CLSN Reaffirms Projection For Second Pre-Planned Interim Efficacy Analysis For Phase III Optima StudyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CHRS licensed U.S. rights from Bioeq AG to Bioeq’s Lucentis® (ranibizumab) biosimilar candidate. Bioeq filed a Biologic Licensing Application with the U.S. Food and Drug Administration in December 2019.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CFRX announced a one-for-ten reverse stock splitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$MESO submitted a biologics license application to the US Food and Drug Administration for Ryoncil to treat children with steroid-refractory acute graft versus host disease, a syndrome characterized by organ inflammation associated with bone marrow transplants.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.